Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
- 1Department of Pharmacy, Fuwai Hospital of Zhengzhou University, Heart Center of Henan Provincial People’s Hospital
- 2Department of Heart Failure, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Heart Center of Henan Provincial People’s Hospital
Abstract
Objective: This study aimed to compare the clinical effects of mavacamten and conventional pharmacotherapy on cardiac function and related disease indicators in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Methods: A retrospective analysis was performed in patients with oHCM who were hospitalized between January 2024 and May 2025. The intervention group included 126 patients who received mavacamten for the first time, while the control group consisted of 134 patients treated with conventional medications. Baseline clinical characteristics, laboratory parameters, and imaging findings were collected. All patients were followed up for 30 weeks after discharge. Changes in relevant clinical indicators were recorded and compared at weeks 6 (W6), 18 (W18), and 30 (W30).
Results: A total of 222 patients (111 per group) completed the 30-week follow-up and were included in the final analysis. After 30 weeks of treatment, the resting left ventricular outflow tract (LVOT) peak gradient fell to 23.76 ± 4.09 mmHg in the intervention group but persisted at 78.49 ± 13.21 mmHg in the control group (t = 24.074, p < 0.001). Similarly, the Valsalva-provoked LVOT peak gradient decreased to 48.95 ± 11.10 mmHg versus 113.59 ± 14.92 mmHg in the control group (t = 21.147, p < 0.001). Left ventricular ejection fraction (LVEF) was 55.12% ± 4.85% in the intervention group and 56.78% ± 5.42% in the control group (p = 0.312), with 9.5% of mavacamten-treated patients experiencing LVEF decline to <50% (vs. 2.2% in controls). N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI) levels were significantly lower in the intervention group (p < 0.05).
Conclusion: Mavacamten indicates significant clinical association with improved outcomes in improving cardiac function and related disease indicators in patients with obstructive hypertrophic cardiomyopathy, with sustained reductions in both resting and provoked LVOT gradients.
Related
- Managing a mavacamten non-responder in obstructive hypertrophic cardiomyopathy: A case report
- Real-World Implementation and Clinical Outcomes of Mavacamten in an Underserved Urban Cohort With Obstructive Hypertrophic Cardiomyopathy
- Long-term mavacamten exposure reduces force and sarcomere density in a human induced pluripotent stem cell–derived model of hypertrophic cardiomyopathy
- Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system.
- Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy
BibTeX
@article{shi2026clinical,
title = {{Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy}},
author = {Ya-Nan Shi and Jia-Jia Huang and Hong-Zhi Liu and Yu Xu and Fang Yuan},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1861248},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1861248/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
AU - Ya-Nan Shi
AU - Jia-Jia Huang
AU - Hong-Zhi Liu
AU - Yu Xu
AU - Fang Yuan
PY - 2026
DA - 2026/10/27
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1861248
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1861248/full
AB - Objective: This study aimed to compare the clinical effects of mavacamten and conventional pharmacotherapy on cardiac function and related disease indicators in patients with obstructive hypertrophic cardiomyopathy (oHCM). Methods: A retrospective analysis was performed in patients with oHCM who were hospitalized between January 2024 and May 2025. The intervention group included 126 patients who received mavacamten for the first time, while the control group consisted of 134 patients treated with conventional medications. Baseline clinical characteristics, laboratory parameters, and imaging findings were collected. All patients were followed up for 30 weeks after discharge. Changes in relevant clinical indicators were recorded and compared at weeks 6 (W6), 18 (W18), and 30 (W30). Results: A total of 222 patients (111 per group) completed the 30-week follow-up and were included in the final analysis. After 30 weeks of treatment, the resting left ventricular outflow tract (LVOT) peak gradient fell to 23.76 ± 4.09 mmHg in the intervention group but persisted at 78.49 ± 13.21 mmHg in the control group (t = 24.074, p < 0.001). Similarly, the Valsalva-provoked LVOT peak gradient decreased to 48.95 ± 11.10 mmHg versus 113.59 ± 14.92 mmHg in the control group (t = 21.147, p < 0.001). Left ventricular ejection fraction (LVEF) was 55.12% ± 4.85% in the intervention group and 56.78% ± 5.42% in the control group (p = 0.312), with 9.5% of mavacamten-treated patients experiencing LVEF decline to <50% (vs. 2.2% in controls). N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI) levels were significantly lower in the intervention group (p < 0.05). Conclusion: Mavacamten indicates significant clinical association with improved outcomes in improving cardiac function and related disease indicators in patients with obstructive hypertrophic cardiomyopathy, with sustained reductions in both resting and provoked LVOT gradients.
SN - 1663-9812
ER -